Skip to content

This Study Aims to Determine the Incidence, of Hepatitis B Diagnosis Among Diabetes Mellitus Patients of 0-80 Years of Age

Incidence of Hepatitis B Diagnosis Among Diabetes Mellitus Patients of 0-80 Years of Age, in the United Kingdom Clinical Practice Research Datalink (CPRD)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02324218
Enrollment
161429
Registered
2014-12-24
Start date
2014-10-31
Completion date
2015-01-31
Last updated
2016-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis B

Keywords

Diabetes mellitus, Hepatitis B, Incidence

Brief summary

This study is being conducted to assess the risk of hepatitis B (HepB) diagnosis among diabetes mellitus (DM) and non-DM patients of 0-80 years of age with in a large population-based cohort in United Kingdom (UK) using data from the CPRD database.

Detailed description

The study is a retrospective, observational, descriptive, cohort study, in DM and non-DM patients of 0-80 years of age. As a first step the eligible baseline population from CPRD will be defined as per the data quality qualifiers, which include subjects aged 0-80 years, acceptable for research registered in practices classified as up to standard by the CPRD for the time period 2000- 2012. The following cohorts will be defined from the baseline population: * DM cohort: Patients diagnosed with type 1 or type 2 DM, as confirmed by diagnosis medical codes with or without a DM related drug or monitoring devices prescription. * Non-DM cohort: Patients with the absence of personal history of DM diagnosis or antidiabetic drug or monitoring devices prescriptions. From the above defined cohorts, HepB cases will be identified based on clinical diagnosis codes, Hospital Episodes Statistics (HES) or positive diagnostic laboratory tests results.

Interventions

OTHERData collection

Data extraction from CPRD database of UK.

Sponsors

GlaxoSmithKline
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 80 Years
Healthy volunteers
No

Inclusion criteria

* Subjects, 0 to 80 years of age during the study period. * Subjects acceptable for research as per CPRD definition: * Acceptable flag for research. * Subjects with at least 12 months of observation time at the time of inclusion in the study: * Subjects have to be registered in the CPRD database for at least 12 months at the date of inclusion in the study. * Subjects have to be registered in a general practitioner practice classified as 'up to standard' for at least 12 months at the date of inclusion in the study. * Particular Case of New Born Children. * To ensure inclusion of subjects less than 1 year of age, they will be included regardless their observation time in CPRD. * Inclusion Date * Inclusion criteria will be assessed for each calendar year between the Years 2000 and 2012.

Exclusion criteria

• For the analyses requiring the inclusion of HES data, HES records linked with more than one CPRD patient will be excluded from the analyses.

Design outcomes

Primary

MeasureTime frame
Occurrence of new HepB diagnosis among patients between 0-80 years of age previously diagnosed with DM, between 2000 and 2012, in the UK CPRD or Hospital Episodes Statistics (HES).Up to 12 years
Occurrence of new HepB diagnosis among non-DM patients between 0-80 years of age, in the UK CPRD or HES.Up to 12 years

Secondary

MeasureTime frame
Hospitalisation episode recorded in HES due to HepB infection or complications among patients between 0-80 years of age previously diagnosed with DM and in DM-free (non-DM) patients, in the UK, for whom CPRD-HES linkage is available.Up to 12 years
All cause mortality among HepB cases in the DM and DM-free (non-DM) patients between 0-80 years of age, in the UK.Up to 12 years
HepB cause-specific mortality among DM and DM-free (non-DM) patients between 0-80 years of age, in the UK for whom CPRD-ONS mortality linkage is available.Up to 12 years
New-onset or prevalent HepB diagnosis among new-onset or prevalent DM and DM-free (non-DM) patients between 0-80 years of age, in the UK, regardless of the onset of HepB in relation to the diagnosis of DM.Up to 12 years

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 25, 2026